Bayer investors shrug off major settlement with €17.5bn of demand for new bonds

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Corporate Bonds
High grade and crossover bonds

Bayer investors shrug off major settlement with €17.5bn of demand for new bonds

Mike Turner
July 01, 2020 05:00 pm
unilab_Adobe_230x150
Life scientists researching in laboratory. Female young scientist and her post doctoral supervisor microscoping in their working environment. Healthcare and biotechnology. | kasto - stock.adobe.com

Bayer, the German life sciences company, enjoyed blow-out demand for its €6bn multi-tranche bond issue on Wednesday, days after agreeing to pay up to $10.9bn to settle a lawsuit over claims its weedkiller, Roundup, causes cancer.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Responsible InvestmentDeutsche BankMizuhoCitiUniCreditSRICorporate BondsHigh grade and crossover bonds
MT
Mike Turner
Corporate Debt Editor
Contact
Gift this article